tiprankstipranks
Trending News
More News >
Kura Oncology (KURA)
NASDAQ:KURA
Advertisement

Kura Oncology (KURA) AI Stock Analysis

Compare
651 Followers

Top Page

KURA

Kura Oncology

(NASDAQ:KURA)

Rating:47Neutral
Price Target:
Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company's stock performance reflects these mixed factors.
Positive Factors
Clinical Development
Upcoming milestones include potential approval of ziftomenib for relapsed/refractory NPM1 mutated acute myeloid leukemia and data presentations at key medical congresses.
Financial Position
The company ended the quarter financially strong with $630.7 million in cash, which management believes provides runway into 2027.
Strategic Execution
Analyst reiterates an Outperform (OP) rating, indicating confidence in KURA's strategic execution and future potential.
Negative Factors
Commercial Performance
The Kyowa Kirin profit split may prevent investors from fully valuing Kura's commercial performance, even if the launch is more successful than anticipated.
Investor Skepticism
Investors are rightfully skeptical given the early stage nature of KURA's renewed FTI efforts, limited clinical data available to date for KO-2806, and past disappointments in the FTI space overall.
Market Competition
Kura Oncology may struggle to drive value in the short term due to existing competition in the market for a smaller patient population.

Kura Oncology (KURA) vs. SPDR S&P 500 ETF (SPY)

Kura Oncology Business Overview & Revenue Model

Company DescriptionKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
How the Company Makes MoneyKura Oncology generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company finances its operations through public offerings, partnerships, and collaborations with other pharmaceutical companies. Kura's earnings are significantly influenced by milestone payments and potential royalties from licensing agreements as its drug candidates progress through clinical trials and, if successful, receive regulatory approval. Additionally, the company may engage in strategic partnerships to co-develop or out-license its therapies, which can provide upfront payments and shared revenue streams from eventual product sales.

Kura Oncology Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong clinical trial results, regulatory progress, and financial stability, indicating positive momentum for Kura Oncology's lead program, ziftomenib, and its pipeline. However, increased expenses and net loss present financial challenges. The sentiment is positive overall due to significant advancements and strong financial positioning.
Q2-2025 Updates
Positive Updates
Positive Data from KOMET-001 Trial
Ziftomenib showed promising results in relapsed or refractory NPM1-mutated AML with a CR/CRh rate of 23% and 63% of responders being MRD negative.
FDA Priority Review
FDA accepted the NDA for ziftomenib with a PDUFA target action date of November 30, 2025, indicating positive regulatory progress.
Strong Financial Position
Kura Oncology has $630.7 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into 2027.
Advancements in Pipeline
Progress with next-generation farnesyl transferase inhibitor, KO-2806, with three clinical abstracts accepted for presentation at the 2025 ESMO Congress.
Commercial Readiness for Ziftomenib
Preparations for potential approval are underway, including the building of commercial supply, quality systems, and a sales force.
Negative Updates
Increased Expenses
Research and development expenses rose to $62.8 million from $39.7 million and general and administrative expenses increased to $25.2 million from $16.7 million compared to the second quarter of 2024.
Net Loss Increased
Net loss for the second quarter of 2025 was $66.1 million compared to a net loss of $50.8 million for the second quarter of 2024.
Company Guidance
During the Second Quarter 2025 Kura Oncology financial results call, the company provided detailed guidance on their lead program, ziftomenib, and its potential impact on patients with acute myeloid leukemia (AML). Ziftomenib has shown promising results in the KOMET-001 trial with a CR/CRh rate of 23% in heavily pretreated relapsed/refractory NPM1-mutant AML patients. The FDA has accepted the new drug application for ziftomenib, granting it priority review with a PDUFA date set for November 30, 2025. Kura is preparing for commercialization in collaboration with Kyowa Kirin, anticipating a U.S. market potential of over $7 billion annually for menin inhibitors. The company is also focused on advancing its Phase III frontline trials under the KOMET-017 protocol, targeting up to 50% of AML patients. Additionally, Kura is progressing with its farnesyl transferase inhibitor, KO-2806, with three clinical abstracts accepted for presentation at the 2025 ESMO Congress. Financially, Kura reported collaboration revenue of $15.3 million from their Kyowa Kirin partnership for the second quarter of 2025, with $630.7 million in cash reserves, believed to be sufficient to fund operations into 2027.

Kura Oncology Financial Statement Overview

Summary
Kura Oncology is experiencing revenue growth, yet profitability remains a challenge with negative margins. Strong liquidity is offset by historical financial distress and high leverage. Cash flow management shows improvement, but overall financial health is impacted by ongoing losses.
Income Statement
45
Neutral
Kura Oncology showed positive revenue growth in TTM, moving from no revenues to generating income. However, margins remain negative with a net profit margin of -267.57% and an EBIT margin of -299.21%, reflecting ongoing profitability challenges common in early-stage biotech companies.
Balance Sheet
30
Negative
The company maintains strong liquidity with significant cash reserves but faces high leverage with a debt-to-equity ratio of 0.03. The equity ratio at 48.98% indicates moderate financial stability, yet the negative equity in prior years signals historical financial distress.
Cash Flow
50
Neutral
Kura Oncology shows a slight improvement in cash flow management with positive operating cash flow in the TTM. The free cash flow to net income ratio is strong despite negative net income, indicating efficient cash management amidst ongoing losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue83.28M53.88M0.000.000.000.00
Gross Profit82.64M53.03M-849.00K-759.00K-558.00K-194.00K
EBITDA-207.74M-169.50M-164.96M-134.85M-129.71M-88.85M
Net Income-197.17M-173.98M-152.63M-136.07M-129.91M-89.43M
Balance Sheet
Total Assets682.42M760.16M448.94M456.31M534.05M647.21M
Cash, Cash Equivalents and Short-Term Investments630.73M727.39M423.96M437.99M517.96M633.32M
Total Debt12.96M16.59M17.20M14.02M6.88M14.98M
Total Liabilities376.94M346.52M51.66M36.03M27.44M36.31M
Stockholders Equity305.49M413.64M397.27M420.28M506.61M610.90M
Cash Flow
Free Cash Flow122.86M133.84M-124.99M-110.69M-105.70M-72.00M
Operating Cash Flow124.99M134.32M-124.82M-110.06M-104.55M-69.83M
Investing Cash Flow-91.89M-101.59M15.56M32.63M-126.83M-99.94M
Financing Cash Flow3.67M154.42M94.78M38.56M-3.44M469.33M

Kura Oncology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.22
Price Trends
50DMA
6.61
Positive
100DMA
6.40
Positive
200DMA
7.47
Positive
Market Momentum
MACD
0.49
Negative
RSI
66.51
Neutral
STOCH
77.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KURA, the sentiment is Positive. The current price of 8.22 is above the 20-day moving average (MA) of 7.32, above the 50-day MA of 6.61, and above the 200-day MA of 7.47, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 66.51 is Neutral, neither overbought nor oversold. The STOCH value of 77.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KURA.

Kura Oncology Risk Analysis

Kura Oncology disclosed 73 risk factors in its most recent earnings report. Kura Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Kura Oncology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$631.57M49.633.33%85820.30%
61
Neutral
$629.54M-32.78%-13.37%-1025.90%
60
Neutral
$851.32M181.41%1049.81%7.85%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
47
Neutral
$705.66M-51.11%-1.26%
41
Neutral
$560.64M-53.15%39.03%
41
Neutral
$647.03M-31.21%-5.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KURA
Kura Oncology
8.22
-11.34
-57.98%
ORKA
Oruka Therapeutics
16.35
-11.65
-41.61%
PHAT
Phathom Pharmaceuticals
12.34
-5.26
-29.89%
KROS
Keros Therapeutics
15.59
-38.29
-71.07%
TYRA
Tyra Bioscience
12.65
-8.86
-41.19%
SEPN
Septerna, Inc.
14.43
-6.32
-30.46%

Kura Oncology Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Kura Oncology Announces Leadership Changes and Appointments
Neutral
Jan 6, 2025

Stephen Dale, M.D. resigned as Chief Medical Officer of Kura Oncology to focus on personal health, leading to a settlement agreement entitling him to compensation and extended stock option exercise periods. Following his resignation, Kura Oncology appointed Mollie Leoni, M.D. as Chief Medical Officer and Francis Burrows, Ph.D. as Chief Scientific Officer, indicating a strategic leadership change.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025